Fumaric acid esters

Clinics in Dermatology

Volumn 26, Issue 5, 2008, Pages 522-526

  Yazdi, Martin Rostami ^a   Mrowietz, Ulrich ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FUMADERM; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOMETHYLFUMARIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DIARRHEA; DRUG ACTIVITY; DRUG ADSORPTION; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG TOLERABILITY; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; LYMPHOCYTOPENIA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUVA; REMISSION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

DERMATOLOGIC AGENTS; ESTERS; FUMARATES; HUMANS; PSORIASIS;

EID: 49849096362     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2008.07.001     Document Type: Article

References (30)

1. Schweckendiek W. Treatment of psoriasis vulgaris. Med Monatsschr 13 (1959) 103-104
2. Günther C.H., Schmitt J., and Wozel G. Erfolgreicher Einsatz von Fumarsäureestern bei einer 14-jährigen Patientin mit Psoriasis vulgaris. Haut 15 (2004) 24-27
3. Mrowietz U., Christophers E., and Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 141 (1999) 424-429
4. Mrowietz U., Christophers E., and Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 138 (1998) 456-460
5. Altmeyer P.J., Matthes U., Pawlak F., Hoffmann K., Frosch P.J., Ruppert P., et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30 (1994) 977-981
6. Hoefnagel J.J., Thio H.B., Willemze R., and Bouwes Bavinck J.N. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149 (2003) 363-369
7. Nugteren-Huying W.M., van der Schroeff J.G., Hermans J., and Suurmond D. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 22 2 Pt 1 (1990) 311-312
8. Altmeyer P., Hartwig R., and Matthes U. [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients]. Hautarzt 47 (1996) 190-196
9. Balasubramaniam P., Stevenson O., and Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 150 (2004) 741-746
10. Nieboer C., de Hoop D., van Loenen A.C., Langendijk P.N., and van Dijk E. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 20 (1989) 601-608
11. Nieboer C., de Hoop D., Langendijk P.N., van Loenen A.C., and Gubbels J. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 181 (1990) 33-37
12. Kolbach D.N., and Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 27 (1992) 769-771
13. Thio B., van der Schroeff J.G., Nugteren-Huying W.M., and Vermeer B.J. Long term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm) in psoriasis. J Eur Acad Dermatol Venereol 4 (1995) 35-40
14. Litjens N.H., van Strijen E., van Gulpen C., Mattie H., van Dissel J.T., Thio H.B., et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol 4 (2004) 22
15. Werdenberg D., Joshi R., Wolffram S., Merkle H.P., and Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 24 (2003) 259-273
16. Litjens N.H., Burggraaf J., van Strijen E., van Gulpen C., Mattie H., Schoemaker R.C., et al. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol 58 (2004) 429-432
17. Mrowietz U., and Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Biol 11 (2005) 43-48
18. Nestle F.O., Turka L.A., and Nickoloff B.J. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest 94 (1994) 202-209
19. Prinz J.C. Which T cells cause psoriasis?. Clin Exp Dermatol 24 (1999) 291-295
20. Altmeyer P., Höxtermann S., and Auer T. Verlaufsbeobachtungen der Lymphozytensubpopulationen bei Psoriasis-Patienten unter oraler Therapie mit Fumaraten. Akt Dermatol 22 (1996) 272-277
21. Bacharach-Buhles M., Pawlak F.M., Matthes U., Joshi R.K., and Altmeyer P. Fumaric acid esters (FAEs) suppress CD 15- and ODP 4-positive cells in psoriasis. Acta Derm Venereol Suppl (Stockh) 186 (1994) 79-82
22. de Jong R., Bezemer A.C., Zomerdijk T.P., Pouw-Kraan T., Ottenhoff T.H., and Nibbering P.H. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 26 (1996) 2067-2074
23. Litjens N.H., Rademaker M., Ravensbergen B., Rea D., van der Plas M.J., Thio B., et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 34 (2004) 565-575
24. Zhu K., and Mrowietz U. Inhibition of dendritic cell differentiation by fumaric acid esters. J Invest Dermatol 116 (2001) 203-208
25. Litjens N.H., Rademaker M., Ravensbergen B., Thio H.B., van Dissel J.T., and Nibbering P.H. Effects of monomethylfumarate on dendritic cell differentiation. Br J Dermatol 154 (2006) 211-217
26. Nibbering P.H., Thio B., Zomerdijk T.P., Bezemer A.C., Beijersbergen R.L., and van Furth R. Effects of monomethylfumarate on human granulocytes. J Invest Dermatol 101 (1993) 37-42
27. Zhu K., and Mrowietz U. Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters. Arch Dermatol Res 297 (2005) 170-176
28. Loewe R., Holnthoner W., Groger M., Pillinger M., Gruber F., Mechtcheriakova D., et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 168 (2002) 4781-4787
29. Nelson K.C., Carlson J.L., Newman M.L., Sternberg Jr. P., Jones D.P., Kavanagh T.J., et al. Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 40 (1999) 1927-1935
30. Exner R., Wessner B., Manhart N., and Roth E. Therapeutic potential of glutathione. Wien Klin Wochenschr 112 (2000) 610-616